Ontology highlight
ABSTRACT: Background
Antibodies to key Plasmodium falciparum surface antigens have been shown to be important effectors that mediate clinical immunity to malaria. The cross-strain fraction of anti-malarial antibodies may however be required to achieve strain-transcending immunity. Such antibody responses against Plasmodium falciparum apical membrane antigen 1 (PfAMA1), a vaccine target molecule that is expressed in both liver and blood stages of the parasite, can be elicited through immunization with a mixture of allelic variants of the parasite molecule. Cross-strain antibodies are most likely elicited against epitopes that are shared by the allelic antigens in the vaccine cocktail.Methods
A standard competition ELISA was used to address whether the antibody response can be further
SUBMITTER: Kusi KA
PROVIDER: S-EPMC3050776 | biostudies-literature | 2011 Feb
REPOSITORIES: biostudies-literature